EU/3/18/2003

About

On 21 March 2018, orphan designation (EU/3/18/2003) was granted by the European Commission to Pharmadev Healthcare Ltd, Ireland, for ribavirin for the treatment of Lassa fever.

The sponsor’s address was updated in April 2021.

Key facts

Active substance
Ribavirin
Disease / condition
Treatment of Lassa fever
Date of first decision
21/02/2018
Outcome
Positive
EU designation number
EU/3/18/2003

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Pharmadev Healthcare Ltd
The Black Church
Saint Mary's Place North
Dublin 7
Dublin D07 P4AX
Ireland
Tel. +353 56 77 06 537
E-mail: jlbarnoux@pharmadevhealthcare.eu

 

 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating